HSBC Holdings’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.1M Sell
63,856
-56,704
-47% -$848K ﹤0.01% 1897
2026
Q2
$1.78M Buy
+120,560
New +$2.14M ﹤0.01% 1640
2026
Q1
– Sell
-98,766
Closed -$1.72M – 3201
2025
Q4
$1.72M Buy
+98,766
New +$1.86M ﹤0.01% 1639
2025
Q2
– Sell
-10,672
Closed -$204K – 3222
2025
Q1
$204K Sell
10,672
-28
-0.3% -$562 ﹤0.01% 2608
2024
Q4
$188K Buy
+10,700
New +$207K ﹤0.01% 2736
2020
Q4
– Sell
-27,342
Closed -$94K – 3134
2020
Q3
$94K Sell
27,342
-123,633
-82% -$428K ﹤0.01% 2629
2020
Q2
$448K Sell
150,975
-40,508
-21% -$140K ﹤0.01% 1907
2020
Q1
$458K Buy
+191,483
New +$329K ﹤0.01% 1824

Other funds holding SMMT

HSBC Holdings's SMMT Position: Q3 2026 in Review

HSBC Holdings reduced its Summit Therapeutics (SMMT) stake by 47% in Q3 2026, selling an estimated $848K and leaving 63,856 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

HSBC Holdings first reported a position in SMMT in Q1 2020 and has held it in 8 quarters since. The position peaked at $1.78M in Q2 2026. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • HSBC Holdings held 63,856 shares of Summit Therapeutics worth $1.1M as of Q3 2026.
  • HSBC Holdings sold 56,704 Summit Therapeutics shares in Q3 2026, an estimated $848K.
  • Summit Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #1897 holding.
  • HSBC Holdings first reported a position in Summit Therapeutics in Q1 2020 and has held it in 8 quarters since.
  • HSBC Holdings's Summit Therapeutics position peaked at $1.78M in Q2 2026.
  • 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.